Talphera (TLPH) Cash from Financing Activities (2010 - 2026)
Talphera (TLPH) posted Cash from Financing Activities of -$261000.0 for Q2 2026, down 106.46% on a QoQ basis from $4.0 million in Q1 2026, and down 106.0% year-over-year from $4.4 million in Q2 2025.
Analysis
Talphera (TLPH) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Talphera has reported Cash from Financing Activities for 17 years, with the latest figure at -$261000.0 in Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 106.0% year-over-year to -$261000.0 in Q2 2026; TTM through Jun 2026 was $22.2 million, a 406.76% increase from a year earlier, with the FY2025 full-year figure at $22.7 million, up 88.81% from the prior year.
- Cash from Financing Activities was -$261000.0 for Q2 2026 at Talphera, down from $4.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $17.0 million in Q3 2025, with the low at -$3.3 million in Q2 2023.
- Average Cash from Financing Activities over 5 years is $2.6 million, with a median of $12500.0 recorded in 2024.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities tumbled 106.09% in 2022, then jumped 80960.0% in 2026.
- Over 5 years, Cash from Financing Activities stood at $5.3 million in 2022, then slumped by 101.28% to -$68000.0 in 2023, then jumped by 144.12% to $30000.0 in 2024, then surged by 4576.67% to $1.4 million in 2025, then plunged by 118.6% to -$261000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$261000.0 (Q2 2026), $4.0 million (Q1 2026), and $1.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | -261,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -261,000.00 |
| Mar 31, 2026 | 4.04 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 16.99 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | -5,000.00 |
| Sep 30, 2024 | 30,000.00 |
| Mar 31, 2024 | 12.01 Mn |
| Dec 31, 2023 | -68,000.00 |
| Sep 30, 2023 | 8.94 Mn |
| Jun 30, 2023 | -3.33 Mn |
| Mar 31, 2023 | -2.07 Mn |
| Dec 31, 2022 | 5.30 Mn |
| Sep 30, 2022 | -1.64 Mn |
| Jun 30, 2022 | -2.08 Mn |
| Mar 31, 2022 | -2.08 Mn |
| Dec 31, 2021 | 11.84 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -2.08 Mn |
| Mar 31, 2021 | 34.22 Mn |